Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 76 entries
Sorted by: Best Match Show Resources per page
Intracranial calcification in a uremic infant with Wilms' tumor in a solitary kidney.

CEN case reports

Matsukura H, Ibuki K, Nomura K, Higashiyama H, Takasaki A, Miyawaki T, Aikawa A, Kanegane H.
PMID: 28509067
CEN Case Rep. 2012 Nov;1(2):86-89. doi: 10.1007/s13730-012-0019-0. Epub 2012 Jun 08.

Wilms' tumor (WT), also called nephroblastoma, is an embryonic neoplasm of the developing kidney. A previously healthy Japanese female infant had WT in a single kidney without associated congenital malformations. Preoperative chemotherapy was started for the preservation of renal...

Cite
Matsukura H, Ibuki K, Nomura K, et al. Intracranial calcification in a uremic infant with Wilms' tumor in a solitary kidney. CEN Case Rep. 2012;1(2):86-89doi: 10.1007/s13730-012-0019-0.
Matsukura, H., Ibuki, K., Nomura, K., Higashiyama, H., Takasaki, A., Miyawaki, T., Aikawa, A., & Kanegane, H. (2012). Intracranial calcification in a uremic infant with Wilms' tumor in a solitary kidney. CEN case reports, 1(2), 86-89. https://doi.org/10.1007/s13730-012-0019-0
Matsukura, Hiro, et al. "Intracranial calcification in a uremic infant with Wilms' tumor in a solitary kidney." CEN case reports vol. 1,2 (2012): 86-89. doi: https://doi.org/10.1007/s13730-012-0019-0
Matsukura H, Ibuki K, Nomura K, Higashiyama H, Takasaki A, Miyawaki T, Aikawa A, Kanegane H. Intracranial calcification in a uremic infant with Wilms' tumor in a solitary kidney. CEN Case Rep. 2012 Nov;1(2):86-89. doi: 10.1007/s13730-012-0019-0. Epub 2012 Jun 08. PMID: 28509067; PMCID: PMC5413644.
Copy Download .nbib Format: NLM
A Novel PHEX Gene Mutation in a Patient with Sporadic Hypophosphatemic Rickets.

Endocrinology and metabolism (Seoul, Korea)

Kang YE, Hong JH, Kim J, Joung KH, Kim HJ, Ku BJ, Kim KS.
PMID: 25031893
Endocrinol Metab (Seoul). 2014 Jun;29(2):195-201. doi: 10.3803/EnM.2014.29.2.195. Epub 2014 Jun 26.

Phosphate regulating gene with homologies to endopeptidases on the X-chromosome (PHEX) is a common cause of X-linked hypophosphatemic (XLH) rickets. Diverse PHEX gene mutations have been reported; however, gene mutations in sporadic rickets are less common than in XLH...

Cite
Kang YE, Hong JH, Kim J, et al. A Novel PHEX Gene Mutation in a Patient with Sporadic Hypophosphatemic Rickets. Endocrinol Metab (Seoul). 2014;29(2):195-201doi: 10.3803/EnM.2014.29.2.195.
Kang, Y. E., Hong, J. H., Kim, J., Joung, K. H., Kim, H. J., Ku, B. J., & Kim, K. S. (2014). A Novel PHEX Gene Mutation in a Patient with Sporadic Hypophosphatemic Rickets. Endocrinology and metabolism (Seoul, Korea), 29(2), 195-201. https://doi.org/10.3803/EnM.2014.29.2.195
Kang, Yea Eun, et al. "A Novel PHEX Gene Mutation in a Patient with Sporadic Hypophosphatemic Rickets." Endocrinology and metabolism (Seoul, Korea) vol. 29,2 (2014): 195-201. doi: https://doi.org/10.3803/EnM.2014.29.2.195
Kang YE, Hong JH, Kim J, Joung KH, Kim HJ, Ku BJ, Kim KS. A Novel PHEX Gene Mutation in a Patient with Sporadic Hypophosphatemic Rickets. Endocrinol Metab (Seoul). 2014 Jun;29(2):195-201. doi: 10.3803/EnM.2014.29.2.195. Epub 2014 Jun 26. PMID: 25031893; PMCID: PMC4091495.
Copy Download .nbib Format: NLM
Effects of combined alendronate and alfacalcidol on prevention of fractures in osteoporosis patients: a network meta-analysis.

International journal of clinical and experimental medicine

Shao HB, Yao YM, Wang ZY, Zhang QF, Wei W.
PMID: 26550211
Int J Clin Exp Med. 2015 Aug 15;8(8):12935-41. eCollection 2015.

BACKGROUND: Published literatures report controversial results about the effect of combined treatment with alendronate and alfacalcidol for the prevention of fractures in osteoporosis patients.METHODS: Seven common databases were searched for related randomized controlled trials published up to April, 2015....

Cite
Shao HB, Yao YM, Wang ZY, et al. Effects of combined alendronate and alfacalcidol on prevention of fractures in osteoporosis patients: a network meta-analysis. Int J Clin Exp Med. 2015;8(8):12935-41
Shao, H. B., Yao, Y. M., Wang, Z. Y., Zhang, Q. F., & Wei, W. (2015). Effects of combined alendronate and alfacalcidol on prevention of fractures in osteoporosis patients: a network meta-analysis. International journal of clinical and experimental medicine, 8(8), 12935-41.
Shao, Hong-Bo, et al. "Effects of combined alendronate and alfacalcidol on prevention of fractures in osteoporosis patients: a network meta-analysis." International journal of clinical and experimental medicine vol. 8,8 (2015): 12935-41.
Shao HB, Yao YM, Wang ZY, Zhang QF, Wei W. Effects of combined alendronate and alfacalcidol on prevention of fractures in osteoporosis patients: a network meta-analysis. Int J Clin Exp Med. 2015 Aug 15;8(8):12935-41. eCollection 2015. PMID: 26550211; PMCID: PMC4612896.
Copy Download .nbib Format: NLM
Efficacy of Alfacalcidol on PEG-IFN/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study.

Hepatitis monthly

Atsukawa M, Tsubota A, Shimada N, Kondo C, Itokawa N, Nakagawa A, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Narahara Y, Nakatsuka K, Iwakiri K, Kawamoto C, Sakamoto C.
PMID: 24403915
Hepat Mon. 2013 Dec 23;13(12):e14872. doi: 10.5812/hepatmon.14872. eCollection 2013.

BACKGROUND: Serum vitamin D concentration is reported to show a decrease in older age. Patients with chronic hepatitis C (CHC) in Japan are older on average than those in Western countries. Moreover, the outcome of pegylated-interferon (PEG-IFN)/ ribavirin therapy...

Cite
Atsukawa M, Tsubota A, Shimada N, et al. Efficacy of Alfacalcidol on PEG-IFN/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study. Hepat Mon. 2013;13(12):e14872doi: 10.5812/hepatmon.14872.
Atsukawa, M., Tsubota, A., Shimada, N., Kondo, C., Itokawa, N., Nakagawa, A., Hashimoto, S., Fukuda, T., Matsushita, Y., Kidokoro, H., Narahara, Y., Nakatsuka, K., Iwakiri, K., Kawamoto, C., & Sakamoto, C. (2013). Efficacy of Alfacalcidol on PEG-IFN/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study. Hepatitis monthly, 13(12), e14872. https://doi.org/10.5812/hepatmon.14872
Atsukawa, Masanori, et al. "Efficacy of Alfacalcidol on PEG-IFN/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study." Hepatitis monthly vol. 13,12 (2013): e14872. doi: https://doi.org/10.5812/hepatmon.14872
Atsukawa M, Tsubota A, Shimada N, Kondo C, Itokawa N, Nakagawa A, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Narahara Y, Nakatsuka K, Iwakiri K, Kawamoto C, Sakamoto C. Efficacy of Alfacalcidol on PEG-IFN/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study. Hepat Mon. 2013 Dec 23;13(12):e14872. doi: 10.5812/hepatmon.14872. eCollection 2013. PMID: 24403915; PMCID: PMC3877658.
Copy Download .nbib Format: NLM
Impact of intercurrent illness on calcium homeostasis in children with hypoparathyroidism: a case series.

Endocrine connections

Chinoy A, Skae M, Babiker A, Kendall D, Mughal MZ, Padidela R.
PMID: 28993435
Endocr Connect. 2017 Nov;6(8):589-594. doi: 10.1530/EC-17-0234.

BACKGROUND: Hypoparathyroidism is characterised by hypocalcaemia, and standard management is with an active vitamin D analogue and adequate oral calcium intake (dietary and/or supplements). Little is described in the literature about the impact of intercurrent illnesses on calcium homeostasis...

Cite
Chinoy A, Skae M, Babiker A, et al. Impact of intercurrent illness on calcium homeostasis in children with hypoparathyroidism: a case series. Endocr Connect. 2017;6(8):589-594doi: 10.1530/EC-17-0234.
Chinoy, A., Skae, M., Babiker, A., Kendall, D., Mughal, M. Z., & Padidela, R. (2017). Impact of intercurrent illness on calcium homeostasis in children with hypoparathyroidism: a case series. Endocrine connections, 6(8), 589-594. https://doi.org/10.1530/EC-17-0234
Chinoy, A, et al. "Impact of intercurrent illness on calcium homeostasis in children with hypoparathyroidism: a case series." Endocrine connections vol. 6,8 (2017): 589-594. doi: https://doi.org/10.1530/EC-17-0234
Chinoy A, Skae M, Babiker A, Kendall D, Mughal MZ, Padidela R. Impact of intercurrent illness on calcium homeostasis in children with hypoparathyroidism: a case series. Endocr Connect. 2017 Nov;6(8):589-594. doi: 10.1530/EC-17-0234. PMID: 28993435; PMCID: PMC5633055.
Copy Download .nbib Format: NLM
[Renal failure and vitamin D].

Clinical calcium

Brown AJ, Dusso AS, Slatopolsky E.
PMID: 15775356
Clin Calcium. 2002 Jun;12(6):711-23. doi: CliCa0206711723.

Secondary hyperparathyroidism (2HPT), a common disorder in patients with chronic renal failure, develops in response to phosphate retention and low serum 1,25-dihydroxyvitamin D(3) [1,25 (OH) (2)D(3), calcitriol] . Replacement therapy with calcitriol or its precursor 1alpha-hydroxyvitamin D(3) [1alpha (OH)...

Cite
Brown AJ, Dusso AS, Slatopolsky E. [Renal failure and vitamin D]. Clin Calcium. 2002;12(6):711-23doi: CliCa0206711723.
Brown, A. J., Dusso, A. S., & Slatopolsky, E. (2002). [Renal failure and vitamin D]. Clinical calcium, 12(6), 711-23. https://doi.org/CliCa0206711723
Brown, Alex J, et al. "[Renal failure and vitamin D]." Clinical calcium vol. 12,6 (2002): 711-23. doi: https://doi.org/CliCa0206711723
Brown AJ, Dusso AS, Slatopolsky E. [Renal failure and vitamin D]. Clin Calcium. 2002 Jun;12(6):711-23. doi: CliCa0206711723. Japanese. PMID: 15775356.
Copy Download .nbib Format: NLM
Vitamin d receptor activators and clinical outcomes in chronic kidney disease.

International journal of nephrology

Gravellone L, Rizzo MA, Martina V, Mezzina N, Regalia A, Gallieni M.
PMID: 21647319
Int J Nephrol. 2011;2011:419524. doi: 10.4061/2011/419524. Epub 2011 May 15.

Vitamin D deficiency appears to be an underestimated risk factor for cardiovascular disease in patients with chronic kidney disease. Evidence from both basic science and clinical studies supports the possible protective role of vitamin D beyond its effect on...

Cite
Gravellone L, Rizzo MA, Martina V, et al. Vitamin d receptor activators and clinical outcomes in chronic kidney disease. Int J Nephrol. 2011;2011:419524doi: 10.4061/2011/419524.
Gravellone, L., Rizzo, M. A., Martina, V., Mezzina, N., Regalia, A., & Gallieni, M. (2011). Vitamin d receptor activators and clinical outcomes in chronic kidney disease. International journal of nephrology, 2011419524. https://doi.org/10.4061/2011/419524
Gravellone, Luciana, et al. "Vitamin d receptor activators and clinical outcomes in chronic kidney disease." International journal of nephrology vol. 2011 (2011): 419524. doi: https://doi.org/10.4061/2011/419524
Gravellone L, Rizzo MA, Martina V, Mezzina N, Regalia A, Gallieni M. Vitamin d receptor activators and clinical outcomes in chronic kidney disease. Int J Nephrol. 2011;2011:419524. doi: 10.4061/2011/419524. Epub 2011 May 15. PMID: 21647319; PMCID: PMC3106992.
Copy Download .nbib Format: NLM
Do the benefits of alendronate for premenopausal women on high-dose glucocorticoids outweigh the risks?.

Nature clinical practice. Rheumatology

Lems WF, Geusens PP.
PMID: 19182812
Nat Clin Pract Rheumatol. 2009 Feb;5(2):74-5. doi: 10.1038/ncprheum0991.

Few data are available on the prevention of fracture in glucocorticoid-treated premenopausal women with autoimmune disorders such as systemic lupus erythematosus. In this setting, Okada et al. compared the effect of coadministration of alfacalcidol alone with that of alfacalcidol...

Cite
Lems WF, Geusens PP. Do the benefits of alendronate for premenopausal women on high-dose glucocorticoids outweigh the risks?. Nat Clin Pract Rheumatol. 2009;5(2):74-5doi: 10.1038/ncprheum0991.
Lems, W. F., & Geusens, P. P. (2009). Do the benefits of alendronate for premenopausal women on high-dose glucocorticoids outweigh the risks?. Nature clinical practice. Rheumatology, 5(2), 74-5. https://doi.org/10.1038/ncprheum0991
Lems, William F, and Geusens, Piet P. "Do the benefits of alendronate for premenopausal women on high-dose glucocorticoids outweigh the risks?." Nature clinical practice. Rheumatology vol. 5,2 (2009): 74-5. doi: https://doi.org/10.1038/ncprheum0991
Lems WF, Geusens PP. Do the benefits of alendronate for premenopausal women on high-dose glucocorticoids outweigh the risks?. Nat Clin Pract Rheumatol. 2009 Feb;5(2):74-5. doi: 10.1038/ncprheum0991. PMID: 19182812.
Copy Download .nbib Format: NLM
Seven years' experience with etidronate in a woman with anorexia nervosa and vertebral fractures.

Therapeutics and clinical risk management

Iwamoto J, Sato Y, Uzawa M, Takeda T, Matsumoto H.
PMID: 21845050
Ther Clin Risk Manag. 2011;7:275-81. doi: 10.2147/TCRM.S21357. Epub 2011 Jul 05.

We report the case of a 30-year-old Japanese woman with anorexia nervosa and vertebral fractures who was treated with etidronate. She had a history of anorexia nervosa, chronic back pain, osteoporosis, and multiple vertebral fractures (morphometric fractures) that responded...

Cite
Iwamoto J, Sato Y, Uzawa M, et al. Seven years' experience with etidronate in a woman with anorexia nervosa and vertebral fractures. Ther Clin Risk Manag. 2011;7:275-81doi: 10.2147/TCRM.S21357.
Iwamoto, J., Sato, Y., Uzawa, M., Takeda, T., & Matsumoto, H. (2011). Seven years' experience with etidronate in a woman with anorexia nervosa and vertebral fractures. Therapeutics and clinical risk management, 7275-81. https://doi.org/10.2147/TCRM.S21357
Iwamoto, Jun, et al. "Seven years' experience with etidronate in a woman with anorexia nervosa and vertebral fractures." Therapeutics and clinical risk management vol. 7 (2011): 275-81. doi: https://doi.org/10.2147/TCRM.S21357
Iwamoto J, Sato Y, Uzawa M, Takeda T, Matsumoto H. Seven years' experience with etidronate in a woman with anorexia nervosa and vertebral fractures. Ther Clin Risk Manag. 2011;7:275-81. doi: 10.2147/TCRM.S21357. Epub 2011 Jul 05. PMID: 21845050; PMCID: PMC3150473.
Copy Download .nbib Format: NLM
The Effects of Olmesartan and Alfacalcidol on Renoprotection and klotho Gene Expression in 5/6 Nephrectomized Spontaneously Hypertensive Rats.

Yonago acta medica

Fukui T, Munemura C, Maeta S, Ishida C, Murawaki Y.
PMID: 24031129
Yonago Acta Med. 2011 Sep;54(3):49-58. Epub 2011 Sep 01.

Recently, an angiotensin inhibitor has been shown to upregulate the klotho mRNA level in chronic renal failure. In addition, the administration of vitamin D has been reported to improve the mortality of patients with chronic renal failure. In this...

Cite
Fukui T, Munemura C, Maeta S, et al. The Effects of Olmesartan and Alfacalcidol on Renoprotection and klotho Gene Expression in 5/6 Nephrectomized Spontaneously Hypertensive Rats. Yonago Acta Med. 2011;54(3):49-58
Fukui, T., Munemura, C., Maeta, S., Ishida, C., & Murawaki, Y. (2011). The Effects of Olmesartan and Alfacalcidol on Renoprotection and klotho Gene Expression in 5/6 Nephrectomized Spontaneously Hypertensive Rats. Yonago acta medica, 54(3), 49-58.
Fukui, Takeaki, et al. "The Effects of Olmesartan and Alfacalcidol on Renoprotection and klotho Gene Expression in 5/6 Nephrectomized Spontaneously Hypertensive Rats." Yonago acta medica vol. 54,3 (2011): 49-58.
Fukui T, Munemura C, Maeta S, Ishida C, Murawaki Y. The Effects of Olmesartan and Alfacalcidol on Renoprotection and klotho Gene Expression in 5/6 Nephrectomized Spontaneously Hypertensive Rats. Yonago Acta Med. 2011 Sep;54(3):49-58. Epub 2011 Sep 01. PMID: 24031129; PMCID: PMC3763788.
Copy Download .nbib Format: NLM
The prevention and treatment of glucocorticoid-induced osteopaenia in juvenile rheumatic disease: A randomised double-blind controlled trial.

EClinicalMedicine

Rooney M, Bishop N, Davidson J, Beresford MW, Pilkington C, Donagh JM, Wyatt S, Gardner-Medwin J, Satyapal R, Clinch J, Foster H, Elliott M, Verghis R.
PMID: 31388666
EClinicalMedicine. 2019 Jul 03;12:79-87. doi: 10.1016/j.eclinm.2019.06.004. eCollection 2019 Jul.

BACKGROUND: Children and young people (CYP) with chronic rheumatic conditions; Juvenile Idiopathic Arthritis, Juvenile Systemic Lupus Erythematosus, Juvenile Dermatomyositis and Juvenile Vasculitis, treated with steroids, have low bone density, increased fracture risk and are likely to have suboptimal peak...

Cite
Rooney M, Bishop N, Davidson J, et al. The prevention and treatment of glucocorticoid-induced osteopaenia in juvenile rheumatic disease: A randomised double-blind controlled trial. EClinicalMedicine. 2019;12:79-87doi: 10.1016/j.eclinm.2019.06.004.
Rooney, M., Bishop, N., Davidson, J., Beresford, M. W., Pilkington, C., Donagh, J. M., Wyatt, S., Gardner-Medwin, J., Satyapal, R., Clinch, J., Foster, H., Elliott, M., Verghis, R. (2019). The prevention and treatment of glucocorticoid-induced osteopaenia in juvenile rheumatic disease: A randomised double-blind controlled trial. EClinicalMedicine, 1279-87. https://doi.org/10.1016/j.eclinm.2019.06.004
Rooney, Madeleine, et al. "The prevention and treatment of glucocorticoid-induced osteopaenia in juvenile rheumatic disease: A randomised double-blind controlled trial." EClinicalMedicine vol. 12 (2019): 79-87. doi: https://doi.org/10.1016/j.eclinm.2019.06.004
Rooney M, Bishop N, Davidson J, Beresford MW, Pilkington C, Donagh JM, Wyatt S, Gardner-Medwin J, Satyapal R, Clinch J, Foster H, Elliott M, Verghis R. The prevention and treatment of glucocorticoid-induced osteopaenia in juvenile rheumatic disease: A randomised double-blind controlled trial. EClinicalMedicine. 2019 Jul 03;12:79-87. doi: 10.1016/j.eclinm.2019.06.004. eCollection 2019 Jul. PMID: 31388666; PMCID: PMC6677647.
Copy Download .nbib Format: NLM
USE OF TERIPARATIDE IN A FOUR YEAR OLD PATIENT WITH AUTOSOMAL DOMINANT HYPOCALCAEMIA.

Archives of disease in childhood

Fox A, Gilbert R.
PMID: 27540249
Arch Dis Child. 2016 Sep;101(9):e2. doi: 10.1136/archdischild-2016-311535.66.

AIM: We report the effective use of the synthetic parathyroid hormone (PTH) teriparatide to treat a 4 year old boy with autosomal dominant hypocalcaemia.BACKGROUND: Autosomal Dominant hypocalcaemia is characterised by hypocalcaemia with a lack of parathyroid hormone (PTH) response...

Cite
Fox A, Gilbert R. USE OF TERIPARATIDE IN A FOUR YEAR OLD PATIENT WITH AUTOSOMAL DOMINANT HYPOCALCAEMIA. Arch Dis Child. 2016;101(9):e2doi: 10.1136/archdischild-2016-311535.66.
Fox, A., & Gilbert, R. (2016). USE OF TERIPARATIDE IN A FOUR YEAR OLD PATIENT WITH AUTOSOMAL DOMINANT HYPOCALCAEMIA. Archives of disease in childhood, 101(9), e2. https://doi.org/10.1136/archdischild-2016-311535.66
Fox, Andy, and Gilbert, Rodney. "USE OF TERIPARATIDE IN A FOUR YEAR OLD PATIENT WITH AUTOSOMAL DOMINANT HYPOCALCAEMIA." Archives of disease in childhood vol. 101,9 (2016): e2. doi: https://doi.org/10.1136/archdischild-2016-311535.66
Fox A, Gilbert R. USE OF TERIPARATIDE IN A FOUR YEAR OLD PATIENT WITH AUTOSOMAL DOMINANT HYPOCALCAEMIA. Arch Dis Child. 2016 Sep;101(9):e2. doi: 10.1136/archdischild-2016-311535.66. PMID: 27540249.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 76 entries